Abstract
Trans-translation is a unique bacterial ribosome rescue system that plays important roles in the tolerance to environmental stresses. It is composed of an ssrA-encoded tmRNA and a protein SmpB. In this study, we examined the role of trans-translation in antibiotic tolerance in Klebsiella pneumoniae and explored whether the inhibition of this mechanism could enhance the bactericidal activities of antibiotics. We found that deletion of the ssrA gene reduced the survival of K. pneumoniae after treatment with kanamycin, tobramycin, azithromycin, and ciprofloxacin, indicating an important role of the trans-translation in bacterial antibiotic tolerance. By using a modified ssrA gene with a 6Ă—His tag we demonstrated that tobramycin suppressed the azithromycin and ciprofloxacin-elicited activation of trans-translation. The results were further confirmed with a trans-translation reporter system that is composed of a normal mCherry gene and a gfp gene without the stop codon. Compared to each individual antibiotic, combination of tobramycin with azithromycin or ciprofloxacin synergistically enhanced the killing activities against planktonic K. pneumoniae cells and improved bacterial clearance in a murine cutaneous abscess infection model. In addition, the combination of tobramycin and ciprofloxacin increased the bactericidal activities against biofilm-associated cells. Overall, our results suggest that the combination of tobramycin with azithromycin or ciprofloxacin is a promising strategy in combating K. pneumoniae infections.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jensen TS, Opstrup KV, Christiansen G, Rasmussen PV, Thomsen ME, Justesen DL, et al. Complement mediated Klebsiella pneumoniae capsule changes. Microbes Infect. 2020;22:19–30.
Kobayashi SD, DeLeo FR. Re-evaluating the potential of immunoprophylaxis and/or immunotherapy for infections caused by multidrug resistant Klebsiella pneumoniae. Future Microbiol. 2018;13:1343–6.
Bassetti M, Righi E, Carnelutti A, Graziano E, Russo A. Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Rev Anti Infect Ther. 2018;16:749–61.
Himeno H, Nameki N, Kurita D, Muto A, Abo T. Ribosome rescue systems in bacteria. Biochimie. 2015;114:102–12.
Huter P, MĂ¼ller C, Arenz S, Beckert B, Wilson DN. Structural basis for ribosome rescue in bacteria. Trends biochemical Sci. 2017;42:669–80.
Keiler KC. Mechanisms of ribosome rescue in bacteria. Nat Rev Microbiol. 2015;13:285–97.
Dulebohn D, Choy J, Sundermeier T, Okan N, Karzai AW. Trans-translation: the tmRNA-mediated surveillance mechanism for ribosome rescue, directed protein degradation, and nonstop mRNA decay. Biochemistry. 2007;46:4681–93.
Ramadoss NS, Zhou X, Keiler KC. TmRNA is essential in Shigella flexneri. PloS One. 2013;8:e57537.
Li J, Ji L, Shi W, Xie J, Zhang Y. Trans-translation mediates tolerance to multiple antibiotics and stresses in Escherichia coli. J Antimicrob Chemother. 2013;68:2477–81.
Luidalepp H, Hallier M, Felden B, Tenson T. TmRNA decreases the bactericidal activity of aminoglycosides and the susceptibility to inhibitors of cell wall synthesis. RNA Biol. 2005;2:70–4.
Brunel R, Charpentier X. Trans-translation is essential in the human pathogen Legionella pneumophila. Sci Rep. 2016;6:37935.
Brito L, Wilton J, FerrĂ¡ndiz MJ, GĂ³mez-Sanz A, de la Campa AG, Amblar M. Absence of tmRNA has a protective effect against fluoroquinolones in Streptococcus pneumoniae. Front Microbiol. 2016;7:2164.
Alumasa JN, Goralski TDP, Keiler KC. Tetrazole-based trans-translation inhibitors kill bacillus anthracis spores to protect host cells. Antimicrob Agents Chemother. 2017;61:e01199–17.
Alumasa JN, Manzanillo PS, Peterson ND, Lundrigan T, Baughn AD, Cox JS, et al. Ribosome rescue inhibitors kill actively growing and nonreplicating persister Mycobacterium tuberculosis Cells. ACS Infect Dis. 2017;3:634–44.
Goralski TD, Dewan KK, Alumasa JN, Avanzato V, Place DE, Markley RL, et al. Inhibitors of ribosome rescue arrest growth of Francisella tularensis at all stages of intracellular replication. Antimicrob Agents Chemother. 2016;60:3276–82.
Ramadoss NS, Alumasa JN, Cheng L, Wang Y, Li S, Chambers BS, et al. Small molecule inhibitors of trans-translation have broad-spectrum antibiotic activity. Proc Natl Acad Sci USA. 2013;110:10282–7.
Huang Y, Alumasa JN, Callaghan LT, Baugh RS, Rae CD, Keiler KC, et al. A small-molecule inhibitor of trans-translation synergistically interacts with cathelicidin antimicrobial peptides to impair survival of Staphylococcus aureus. Antimicrob Agents Chemother. 2019;63:e02362–18.
Ren H, He X, Zou X, Wang G, Li S, Wu Y. Gradual increase in antibiotic concentration affects persistence of Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70:3267–72.
Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Die Pharmazie. 2003;58:447–74.
Corvaisier S, Bordeau V, Felden B. Inhibition of transfer messenger RNA aminoacylation and trans-translation by aminoglycoside antibiotics. J Biol Chem. 2003;278:14788–97.
Roche ED, Sauer RT. Identification of endogenous SsrA-tagged proteins reveals tagging at positions corresponding to stop codons. J Biol Chem. 2001;276:28509–15.
Ren H, Liu Y, Zhou J, Long Y, Liu C, Xia B, et al. Combination of azithromycin and gentamicin for efficient treatment of Pseudomonas aeruginosa infections. J Infect Dis. 2019;220:1667–78.
Chung PY. The emerging problems of Klebsiella pneumoniae infections: carbapenem resistance and biofilm formation. FEMS Microbiol Lett. 2016;363:fnw219.
Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, et al. Tackling antibiotic resistance. Nat Rev Microbiol. 2011;9:894–6.
Spellberg B, Shlaes D. Prioritized current unmet needs for antibacterial therapies. Clin Pharmacol Therapeutics. 2014;96:151–3.
Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517:455–9.
Pletzer D, Mansour SC, Hancock REW. Synergy between conventional antibiotics and anti-biofilm peptides in a murine, sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens. PLoS Pathog. 2018;14:e1007084.
Pletzer D, Mansour SC, Wuerth K, Rahanjam N, Hancock RE. New mouse model for chronic infections by gram-negative bacteria enabling the study of anti-infective efficacy and host-microbe interactions. mBio. 2017;8:e00140–17.
Lin L, Nonejuie P, Munguia J, Hollands A, Olson J, Dam Q, et al. Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-tesistant gram-negative bacterial pathogens. EBioMedicine. 2015;2:690–8.
Goering RV, Sanders CC, Sanders WE Jr. Comparison of 5-episisomicin (Sch 22591), gentamicin, sisomicin, and tobramycin in treatment of experimental Pseudomonas infections in mice. Antimicrob Agents Chemother. 1978;14:824–8.
Yagel SK, Barrett JF, Amaratunga DJ, Frosco MB. In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia. Antimicrob Agents Chemother. 1996;40:2894–7.
LeBel M. Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy. 1988;8:3–33.
Mustaev A, Malik M, Zhao X, Kurepina N, Luan G, Oppegard LM, et al. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding. J Biol Chem. 2014;289:12300–12.
Jeong KS, Ahn J, Khodursky AB. Spatial patterns of transcriptional activity in the chromosome of Escherichia coli. Genome Biol. 2004;5:R86.
Sutormin D, Rubanova N, Logacheva M, Ghilarov D, Severinov K. Single-nucleotide-resolution mapping of DNA gyrase cleavage sites across the Escherichia coli genome. Nucleic Acids Res. 2019;47:1373–88.
Mayer-Hamblett N, Retsch-Bogart G, Kloster M, Accurso F, Rosenfeld M, Albers G, et al. Azithromycin for early pseudomonas infection in Cystic fibrosis. The OPTIMIZE Randomized Trial. Am J Respir Crit Care Med. 2018;198:1177–87.
Mogayzel PJ Jr., Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187:680–9.
Wang Y, Wang S, Chen W, Song L, Zhang Y, Shen Z, et al. CRISPR-Cas9 and CRISPR-assisted cytidine deaminase enable precise and efficient genome editing in Klebsiella pneumoniae. Appl Environ Microbiol. 2018;84:e01834–18.
Leonard SN, Kaatz GW, Rucker LR, Rybak MJ. Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2008;62:1305–10.
Rivardo F, Martinotti MG, Turner RJ, Ceri H. Synergistic effect of lipopeptide biosurfactant with antibiotics against Escherichia coli CFT073 biofilm. Int J Antimicrob Agents. 2011;37:324–31.
Acknowledgements
We would like to thank Dr. Robert E. W. Hancock at the Centre for Microbial Diseases and Immunity Research, Department of Microbiology and Immunology, University of British Columbia for the teaching of the mouse cutaneous abscess model. We would like to thank Dr. Quanjiang Ji at the School of Physical Science and Technology, ShanghaiTech University for kindly providing the K. pneumoniae CRISPR system. This work was supported by National Key Research and Development Project of China (2021YFE0101700, 2017YFE0125600), National Science Foundation of China (31970680, 31970179 and 31870130), Fundamental Research Funds for the Central Universities, Nankai University (63201093), and the Tianjin Municipal Science and Technology Commission (19JCYBJC24700). The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.
Author contributions
W.W., H.R., and D.P. conceived and designed the experiments. H.R., Y.Z., J.Z., C.X., Z.F., X.P., and S.L. performed the experiments. H.R., Y.J., F.B., Z.C., D.P., and W.W. analyzed the data. Y.Z., S.C., J.X., P.W., Yh.Z., G.Z., H.L. provided and characterized the clinical isolates. H.R., D.P., and W.W. wrote the paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Ethical statement
The animal experiments were conducted following the national guidelines on the use of animals in research. The protocol was approved by the Animal Care and Use Committee of the College of Life Sciences, Nankai University (permission number: NK-04-2012).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Ren, H., Zhang, J., Zhou, J. et al. Synergistic bactericidal activities of tobramycin with ciprofloxacin and azithromycin against Klebsiella pneumoniae. J Antibiot 74, 528–537 (2021). https://doi.org/10.1038/s41429-021-00427-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41429-021-00427-0